JB Pharma to acquire GlenmarkRazel brand in India and Nepal for Rs. 314 crore
JB Pharma, one of the fastest growing pharmaceutical companies in India, has entered into an agreement with Glenmark Pharmaceuticals Ltd., to acquire the entire Razel (rosuvastatin) franchise for the India and Nepal region for a whopping Rs. 314 crore. With this acquisition, JB Pharma will complete its cardiac portfolio making it a leader in this segment, as Razel ranks among the top 10 brands in the rosuvastatin molecule category in the country. These brands are focused on the cardiac segment in India and Nepal Commenting on the acquisition, Nikhil Chopra, CEO & whole time director, JB Pharma said,
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
